scholarly journals ETIOPATHOGENESIS AND MANAGEMENT OF WAJAAL-MAFASIL (RHEUMATOID ARTHRITIS): AN EVIDENCE-BASED COMPREHENSIVE REVIEW

2022 ◽  
Vol 12 (6) ◽  
pp. 96-103
Author(s):  
Ansari Umme Ammara Maqbool Ahmad ◽  
Qamar Uddin ◽  
Bhoraniya Abdullah Ismail ◽  
Juveria Jabeen
Keyword(s):  
Rheumatoid Arthritis ◽  
Indian Subcontinent ◽  
Scientific Evidence ◽  
Review Article ◽  
Alternative Source ◽  
Unani Medicine ◽  
Preclinical And Clinical Studies ◽  
Chronic Autoimmune Disease ◽  
Inflammatory Polyarthritis

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by symmetrical inflammatory polyarthritis involving small joints of the hand and feet. It has a global prevalence of 0.8 to 1% in Europe and the Indian subcontinent. Rheumatoid arthritis (Waja‘al-Maf?sil) had been broadly described and managed by the Unani scholars since antiquity. Many pharmacological and non-pharmacological treatment methods are available in the classical Unani literature. The treatment differs for different varieties of morbid humour involved in disease pathogenesis. Treatment aims to reduce morbidity and prevent disability, subsequently improving the quality of life. This review article mainly highlights the management of rheumatoid arthritis mentioned in classical Unani literature and supportive scientific evidence of various preclinical and clinical studies suggesting the potential of Unani medicine. This review article aims to explore the concept of rheumatoid arthritis in the Unani system of medicine to provide a better understanding of disease and its management through the holistic policy of Unani medicine. This review may conclude that Unani treatment can form an alternative source to manage RA.

scholarly journals ADIPOCYTOKINES IN RHEUMATOID ARTHRITIS: LATENT RELATIONASHIP BETWEEN INFLAMMATION AND CARDIOMETABOLIC COMORBIDITIES

2021 ◽  
Vol 21 (1) ◽  
pp. 165-171
Author(s):  
V.M. Zhdan ◽  
M.V. Tkachenko ◽  
M.Yu. Babanina ◽  
Ye.M. Kіtura ◽  
G.V. Volchenko
Keyword(s):  
Rheumatoid Arthritis ◽  
Cardiovascular Disease ◽  
Energy Homeostasis ◽  
Proinflammatory Mediators ◽  
Bone Damage ◽  
Articular Damage ◽  
Preclinical And Clinical Studies ◽  
Chronic Autoimmune Disease ◽  
Necrosis Factor

Rheumatoid arthritis is a chronic autoimmune disease that affects the synovial membrane of the joints and leads to progressive articular damage, disability and reduced quality of life. Despite the emergence of more innovative therapeutic strategies that have improved the duration of remission, rheumatoid arthritis is associated with high levels of comorbidities, infections, malignancies and cardiovascular disease. It is known that some pathogenic proinflammatory mediators in rheumatoid arthritis, such as interleukin-1β (IL-1β) and tumour necrosis factor, may play a central role in the development of cardiovascular disease. Interestingly, various preclinical and clinical studies have shown that biologic agents, who are widely used in the therapy of patients with rheumatoid arthritis, may be effective in the therapy of cardiovascular diseases as well. For this purpose we have studied adipocytokines. Adipocytokines are pleiotropic molecules that are mainly released by white adipose tissue and immune cells. Adipocytokines modulate the function of different tissues and cells, and, in addition to energy homeostasis and metabolism, enhance inflammation, immune response and tissue damage. Adipocytokines may contribute to the proinflammatory conditions in patients with rheumatoid arthritis and the development of bone damage. In addition, they may be associated with the development of cardiovascular disease. In this study, we considered the already known evidence about adipocytokines in the pathogenesis of rheumatoid arthritis, because they are also actively involved in the pathogenesis of cardiovascular disease and are possible biomarkers of prognosis and treatment outcomes, because of their potential, as a possible new therapeutic target.

scholarly journals Proportion and Factors that Associate with Incidence of Hepatotoxicity in Rheumatoid Arthritis Patients Treated with Methotrexate in RSCM Year 2013−2015

2018 ◽  
Vol 10 (1) ◽  
Author(s):  
Rahma Anindya Prathitasari ◽  
Harry Isbagio
Keyword(s):  
Quality Of Life ◽  
Rheumatoid Arthritis ◽  
Autoimmune Disease ◽  
Aspartate Aminotransferase ◽  
Alanine Aminotransferase ◽  
Side Effect ◽  
Normal Limit ◽  
Keywords Rheumatoid Arthritis ◽  
Chronic Autoimmune Disease

Background Rheumatoid arhtirtis (RA) is a chronic autoimmune disease that mainly attacks joints. It may causes joint deformities which leads to lower quality of life of RA patients. RA is treated with metothrexate (MTX) which inhibiting disease progression. MTX is known for its hepatotoxicity side effect, which is described by an elevation of aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) beyond the upper normal limit. Factors that may enhance hepatotoxicity are gender, age, cummulative dose of MTX, and duration therapy of MTX. Prevalence of hepatotoxicity caused by MTX therapy in RA patients in Indonesia is still unknown. The objective of this research is to know the proportion of hepatotoxicity and its associations with the factors that may enhance hepatotoxicity caused by MTX therapy in RA patients in RSCM.Method Data about gender, age, cummulative dose and duration therapy of MTX are obtained from 115 RA patients' medical records.Result Proportion of hepatotoxicity in RA patients treated with MTX in RSCM is 42.60%. Gender, age, cummulative dose and duration therapy of MTX do not significantly enhance hepatotoxicity (p>0.05).Conclusion In conclusion gender, age, cummulative dose and duration therapy of MTX do not have association with hepatotoxicity in RA patients treated with MTX. Keywords: Rheumatoid Arthritis, Methotrexate, Hepatotoxicity

scholarly journals Adipocytokines in Rheumatoid Arthritis: The Hidden Link between Inflammation and Cardiometabolic Comorbidities

2018 ◽  
Vol 2018 ◽  
pp. 1-10 ◽  
Author(s):  
Piero Ruscitti ◽  
Paola Di Benedetto ◽  
Onorina Berardicurti ◽  
Vasiliki Liakouli ◽  
Francesco Carubbi ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Energy Homeostasis ◽  
Interleukin 1 ◽  
High Rate ◽  
Proinflammatory Mediators ◽  
Bone Damage ◽  
Articular Damage ◽  
Preclinical And Clinical Studies ◽  
Chronic Autoimmune Disease

Rheumatoid arthritis is a chronic autoimmune disease affecting typically synovial joints and leading to progressive articular damage, disability, and reduced quality of life. Despite better recent therapeutic strategies improving long-term outcomes, RA is associated with a high rate of comorbidities, infections, malignancies, and cardiovascular disease (CVD). Remarkably, some well-known pathogenic proinflammatory mediators in RA, such as interleukin-1β (IL-1β) and tumor necrosis factor (TNF), may play a pivotal role in the development of CVD. Interestingly, different preclinical and clinical studies have suggested that biologic agents commonly used to treat RA patients may be effective in improving CVD. In this context, the contribution of adipocytokines has been suggested. Adipocytokines are pleiotropic molecules, mainly released by white adipose tissue and immune cells. Adipocytokines modulate the function of different tissues and cells, and in addition to energy homeostasis and metabolism, amplify inflammation, immune response, and tissue damage. Adipocytokines may contribute to the proinflammatory state in RA patients and development of bone damage. Furthermore, they could be associated with the occurrence of CVD. In this study, we reviewed available evidence about adipocytokines in RA, because of their involvement in disease activity, associated CVD, and possible biomarkers of prognosis and treatment outcome and because of their potential as a possible new therapeutic target.

scholarly journals Proportion and Factors that Associate with Incidence of Hepatotoxicity in Rheumatoid Arthritis Patients Treated with Methotrexate in RSCM Year 2013−2015

2018 ◽  
Vol 10 (1) ◽  
Author(s):  
Rahma Anindya Prathitasari ◽  
Harry Isbagio
Keyword(s):  
Quality Of Life ◽  
Rheumatoid Arthritis ◽  
Autoimmune Disease ◽  
Disease Progression ◽  
Alanine Aminotransferase ◽  
Side Effect ◽  
Normal Limit ◽  
Keywords Rheumatoid Arthritis ◽  
Chronic Autoimmune Disease

Background Rheumatoid arhtirtis (RA) is a chronic autoimmune disease that mainly attacks joints. It may causes joint deformities which leads to lower quality of life of RA patients. RA is treated with metothrexate (MTX) which inhibiting disease progression. MTX is known for its hepatotoxicity side effect, which is described by an elevation of aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) beyond the upper normal limit. Factors that may enhance hepatotoxicity are gender, age, cummulative dose of MTX, and duration therapy of MTX. Prevalence of hepatotoxicity caused by MTX therapy in RA patients in Indonesia is still unknown. The objective of this research is to know the proportion of hepatotoxicity and its associations with the factors that may enhance hepatotoxicity caused by MTX therapy in RA patients in RSCM.Method Data about gender, age, cummulative dose and duration therapy of MTX are obtained from 115 RA patients' medical records.Result Proportion of hepatotoxicity in RA patients treated with MTX in RSCM is 42.60%. Gender, age, cummulative dose and duration therapy of MTX do not significantly enhance hepatotoxicity (p>0.05).Conclusion In conclusion gender, age, cummulative dose and duration therapy of MTX do not have association with hepatotoxicity in RA patients treated with MTX. Keywords: Rheumatoid Arthritis, Methotrexate, Hepatotoxicity

scholarly journals CO-MORBIDITY OF CARDIOVASCULAR DISEASES AND RHEUMATOID ARTHRITIS

2017 ◽  
Vol 10 (5) ◽  
pp. 72
Author(s):  
Dharmang Tansukhray Pandya
Keyword(s):  
Rheumatoid Arthritis ◽  
Cardiovascular Diseases ◽  
Management Strategies ◽  
Review Article ◽  
Comorbid Conditions ◽  
Related Risk ◽  
Co Morbidity ◽  
Rheumatic Heart ◽  
Made In

Rheumatoid Arthritis (RA) is a chronic disease related to swelling of joints which leads to restriction in movement due to pain and deformity in mainly in feet, ankle, wrist and fingers. It is an autoimmune disease and the manifestations caused due to its occurrence are not clearly understood. In today’s time, it has been observed that comorbid conditions account for most of the deaths as they influence the outcome of RA and limit therapeutic options. The most common comorbid conditions which are diagnosed in RA patients are generally cardiovascular abnormalities, several infections, certain mental disorders and malignancies. Among which cardiovascular comorbid diseases are the most common kind relating to disorders of heart and blood vessel that eventually leads to severe conditions like angina, myocardial infarction (MI), stroke, rheumatic heart disease and many more. RA affects the quality of life of patients directly or indirectly but it mainly shows a significant increase in the prevalence of cardiovascular diseases. Hence, it is essential to diagnose and understand about the related manifestations when one is suffering from Rheumatoid Arthritis. These studies will aid to make better treatment and management strategies. Hence, an attempt has been made in this review article regarding the epidemiology, impact of both the diseases and related risk factors. It also gives information in brief about the pathological causes of the comorbidity and summarizes measures that may be used in the prevention and treatment of these conditions.

Psychosomatic Features, Compliance and Complementary Therapies in Rheumatoid Arthritis

2020 ◽  
Vol 16 (3) ◽  
pp. 215-223
Author(s):  
Rostislav A. Grekhov ◽  
Galina P. Suleimanova ◽  
Andrei S. Trofimenko ◽  
Liudmila N. Shilova
Keyword(s):  
Quality Of Life ◽  
Rheumatoid Arthritis ◽  
Interpersonal Relationships ◽  
Behavioral Therapy ◽  
Current Data ◽  
Psychotherapeutic Interventions ◽  
And Coping ◽  
Regulation Of Emotion ◽  
The Impact

This review highlights the issue of psychosomatic conditions in rheumatoid arthritis, paying special attention to new researches and trends in this field. Emerging concepts in all the major parts of the problem are covered consecutively, from the impact of chronic musculoskeletal pain on the emotional state to disease influence over quality of life, socio-psychological, and interpersonal relationships. Chronic pain is closely related to emotional responses and coping ability, with a pronounced positive effect of psychotherapeutic interventions, family and social support on it. Psychosexual disorders, anxiety, depression also commonly coexist with rheumatoid arthritis, leading to further decrease in quality of life, low compliance, and high suicide risk. Influence of psychosomatic conditions on the overall treatment effect is usually underestimated by rheumatologists and general practitioners. Psychosomatic considerations are of great importance for up-to-date management of rheumatoid arthritis, as they strongly influence the quality of life, compliance, and thereby disease outcomes. Two major approaches of psychological rehabilitation exist, both coping with pain through the regulation of emotion and psychotherapeutic intervention, which not only helps patients in coping with the disease, but also aimed at improving the overall adaptation of the patient. It includes techniques of relaxation, cognitive-behavioral therapy, and biofeedback therapy. Current data about the efficacy of the additional correcting therapies for patients with rheumatoid arthritis, both emerging and common ones, are discussed in the review.

Sign in / Sign up

Export Citation Format

Share Document